January 10, 2022
D.C. News
  • The Biden administration will re-evaluate its decision to ship three types of monoclonal antibody treatments to states, after data showed that two of the three authorized antibodies may be ineffective against the omicron variant. David Kessler, chief scientific officer for the White House’s COVID-19 response team, said providers shouldn’t use the two uncertain treatments unless they know a patient doesn’t have omicron. (Article here)